psilocybin

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analysts
  If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
  biospace · 7h ago
• STAT+: Experts scrutinize Huidagene’s disclosures after patient death
  Merck and Moderna's mRNA cancer vaccine, an expected nominee to lead the FDA, and more biotech news from The Readout
  stat · 9h ago
• STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
  A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
  stat · 9h ago
• STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
  A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
  stat · 16h ago
• STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
  Experts question technical improvements Huidagene tried when using a Duchenne muscular dystrophy treatment strategy largely abandoned by U.S. companies.
  stat · 18h ago
• STAT+: Nonprofit health system raked in $1.1 billion this year from stake in medical billing firm
  Private equity firms have taken a strong interest in revenue cycle management firms, such as Ensemble.
  stat · 1d ago
• STAT+: Real-world psilocybin data suggest need for close monitoring
  Amylyx reports success in a pivotal trial, biopharma A-listers join a pain-blocking device company board, and more biotech news from The Readout
  stat · 1d ago
• Rebounding biotech funds expected to spur CDMO growth within year
  With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.
  biospace · 1d ago
• Nascent US psychedelic therapy opportunity attracts overseas manufacturers
  Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.
  biospace · 5d ago
• Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout
  It’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in d…
  biospace · 7d ago